Delayed Japan Exchange 10:30:00 2026-07-05 pm EDT 5-day change 1st Jan Change
1,552.50 JPY -0.38% Intraday chart for Nipro Corporation -3.72% +5.11%

Valuation: Nipro Corporation

Market Cap 254B 1.58B 1.38B 1.27B 1.18B 2.24B 150B 2.27B 15.2B 5.91B 73.76B 5.92B 5.79B P/E 2027 *
19.2x
P/E 2028 * 13.9x
Enterprise Value 764B 4.74B 4.14B 3.81B 3.55B 6.73B 451B 6.83B 45.71B 17.77B 222B 17.79B 17.41B EV / Sales 2027 *
1.1x
EV / Sales 2028 * 1.03x
Free-Float
87.38%
Yield 2027 *
2.13%
Yield 2028 * 2.57%
May. 12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
May. 12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
May. 01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
Mar. 11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
Feb. 08 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
Dec. 24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
Nov. 10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
25-06-10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
25-06-09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
25-05-13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
25-05-12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
25-05-12 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
25-05-12 Nipro Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day-0.29%
1 week-3.63%
Current month-1.43%
1 month-9.91%
3 months-4.63%
6 months+4.23%
Current year+5.21%
1 week 1,531
Extreme 1531
1,616
1 month 1,531
Extreme 1531
1,754.5
Current year 1,401
Extreme 1401
1,760.5
1 year 1,305
Extreme 1305
1,760.5
3 years 1,001.5
Extreme 1001.5
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
President 58 2025-06-25
Chief Administrative Officer 57 2025-06-25
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 2025-06-25
Director/Board Member 53 2009-05-31
Director/Board Member 58 2009-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%-3.63%+18.54%+54.32% 1.58B
+3.49%+1.36%-29.04%-11.15% 166B
+5.04%+2.73%-5.88%-4.24% 106B
+2.80%+3.63%+0.09%+55.53% 57.69B
-1.21%-0.70%+54.88%+57.50% 53.78B
+3.39%+1.39%-10.26%-39.27% 43.56B
+3.50%+11.11% - - 36.52B
+3.47%+1.58%-14.08%-44.37% 27.49B
+0.20%+4.24%+64.56%-2.99% 25.84B
+2.78%+1.17%-8.15%-0.33% 21.27B
Average +2.32%+3.91%+7.85%+7.22% 54.04B
Weighted average by Cap. +3.05%+3.78%-3.58%+2.11%

Financials

2027 *2028 *
Net sales 696B 4.31B 3.77B 3.47B 3.23B 6.13B 411B 6.22B 41.61B 16.18B 202B 16.2B 15.85B 727B 4.51B 3.94B 3.62B 3.38B 6.4B 429B 6.5B 43.48B 16.9B 211B 16.92B 16.56B
Net income 13.75B 85.25M 74.53M 68.49M 63.84M 121M 8.12B 123M 822M 320M 3.99B 320M 313M 19.15B 119M 104M 95.37M 88.9M 169M 11.3B 171M 1.14B 445M 5.56B 446M 436M
Net Debt 510B 3.16B 2.77B 2.54B 2.37B 4.49B 301B 4.56B 30.51B 11.86B 148B 11.88B 11.62B 493B 3.06B 2.67B 2.45B 2.29B 4.34B 291B 4.41B 29.47B 11.46B 143B 11.47B 11.22B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
26-07-05 ¥1,552.50 -0.38% 123,500
26-07-03 ¥1,558.50 -0.48% 456,000
26-07-02 ¥1,566.00 +2.09% 693,900
26-07-01 ¥1,534.00 -2.70% 704,000
26-06-30 ¥1,576.50 -2.23% 666,800
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,558.50JPY
Average target price
1,876.00JPY
Spread / Average Target
+20.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock